2013
Autotaxin–Lysophosphatidic Acid Signaling Axis Mediates Tumorigenesis and Development of Acquired Resistance to Sunitinib in Renal Cell Carcinoma
Su SC, Hu X, Kenney PA, Merrill MM, Babaian KN, Zhang XY, Maity T, Yang SF, Lin X, Wood CG. Autotaxin–Lysophosphatidic Acid Signaling Axis Mediates Tumorigenesis and Development of Acquired Resistance to Sunitinib in Renal Cell Carcinoma. Clinical Cancer Research 2013, 19: 6461-6472. PMID: 24122794, PMCID: PMC4191899, DOI: 10.1158/1078-0432.ccr-13-1284.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAnimalsCarcinogenesisCarcinoma, Renal CellCell Line, TumorCell MovementDrug Resistance, NeoplasmFemaleHuman Umbilical Vein Endothelial CellsHumansIndolesKidney NeoplasmsLysophospholipidsMiceMice, Inbred BALB CMice, NudeMicrovesselsNeoplasm InvasivenessPhosphoric Diester HydrolasesPyrrolesSignal TransductionSunitinibTranscriptomeTumor BurdenXenograft Model Antitumor AssaysConceptsLPA receptor 1Lysophosphatidic acidATX-LPAResistance of RCCRenal cell carcinomaGene expression profilesExtracellular lysophospholipase DRCC cell linesTarget genesCell motilityEndothelial cellsExpression profilesIntracellular signalingInvasion responsesRCC tumorigenesisHuman renal cell carcinomaSignaling AxisSensitivity of RCCRCC cellsFunctional roleXenograft modelAltered expressionRenal tumorigenesisCell carcinomaLysophospholipase D
2012
Integration of Surgery and Systemic Therapy for Renal Cell Carcinoma
Kenney PA, Wood CG. Integration of Surgery and Systemic Therapy for Renal Cell Carcinoma. Urologic Clinics Of North America 2012, 39: 211-231. PMID: 22487764, DOI: 10.1016/j.ucl.2012.01.005.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, HormonalCarcinoma, Renal CellChemotherapy, AdjuvantCombined Modality TherapyFemaleHumansImmunotherapyKidney NeoplasmsMaleNeoadjuvant TherapyNeoplasm InvasivenessNeoplasm StagingNephrectomyPrognosisRadiotherapy, AdjuvantRisk AssessmentSurvival AnalysisTreatment OutcomeConceptsRenal cell carcinomaSystemic therapyCell carcinomaMetastatic renal cell carcinomaAdvanced nonmetastatic diseaseUpfront cytoreductive nephrectomyIntegration of surgeryCytoreductive nephrectomyCytoreductive surgeryNeoadjuvant therapyNonmetastatic diseaseAdjuvant therapyMetastatic diseaseAppropriate patientsTherapySurgeryDiseaseCurrent roleNephrectomyFurther studiesCarcinomaPotential benefitsPatientsTrials
2010
Novel ZEB1 expression in bladder tumorigenesis
Kenney PA, Wszolek MF, Rieger‐Christ K, Neto BS, Gould JJ, Harty NJ, Mosquera JM, Zeheb R, Loda M, Darling DS, Libertino JA, Summerhayes IC. Novel ZEB1 expression in bladder tumorigenesis. BJU International 2010, 107: 656-663. PMID: 20735391, DOI: 10.1111/j.1464-410x.2010.09489.x.Peer-Reviewed Original ResearchConceptsEpithelial-mesenchymal transitionTransitional cell carcinomaZEB1 expressionNuclear ZEB1 expressionTissue microarrayBladder tumorsTumor progressionGrade I/IIBladder tumorigenesisMuscle-invasive UCBCancer-specific survivalGrade III tumorsNormal bladder mucosaExpression levelsExpression of ZEB1Underlying cellular changesCell linesBladder cell linesUM-UC-3Bladder tumor progressionProtein expression levelsBladder carcinoma cell lineInvasive UCBWestern blot analysisNodal involvementIdentification of Tumor and Invasion Suppressor Gene Modulators in Bladder Cancer by Different Classes of Histone Deacetylase Inhibitors Using Reverse Phase Protein Arrays
Gould JJ, Kenney PA, Rieger-Christ KM, Neto B, Wszolek MF, LaVoie A, Holway AH, Spurrier B, Austin J, Cammarata BK, Canes D, Libertino JA, Summerhayes IC. Identification of Tumor and Invasion Suppressor Gene Modulators in Bladder Cancer by Different Classes of Histone Deacetylase Inhibitors Using Reverse Phase Protein Arrays. Journal Of Urology 2010, 183: 2395-2402. PMID: 20403623, DOI: 10.1016/j.juro.2010.02.004.Peer-Reviewed Original ResearchConceptsReverse phase protein arrayPhase protein arrayHistone deacetylase inhibitorsInvasive cell linesDeacetylase inhibitorsProtein arraysExpression profilesCell linesProtein expression profilesMS-275Specific protein groupsSuppressor gene expressionHigh-throughput screeningGene expressionGene modulatorsTrichostatin AInvasive linesSuppressor geneBladder carcinoma cell lineProtein groupsFAK expressionCarcinoma cell linesBladder cancerValproic acidThroughput screening
2009
A MicroRNA expression profile defining the invasive bladder tumor phenotype
Wszolek MF, Rieger-Christ KM, Kenney PA, Gould JJ, Neto B, LaVoie AK, Logvinenko T, Libertino JA, Summerhayes IC. A MicroRNA expression profile defining the invasive bladder tumor phenotype. Urologic Oncology Seminars And Original Investigations 2009, 29: 794-801.e1. PMID: 19945312, DOI: 10.1016/j.urolonc.2009.08.024.Peer-Reviewed Original Research